Deutsche Bank initiated coverage of Immunovant with a Buy rating and $50 price target. Based on the recent Phase 1 data for IMVT-1402, the firm sees the program as largely derisked from a safety perspective and thinks it “could ultimately prove to be best-in-class,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMVT:
- TD Cowen starts ‘only pure-play TL1A company’ Spyre Therapeutics at Outperform
- Roivant notes Immunovant data from Phase 1 IMVT-1402 trial
- Immunovant announces results from 600 mg MAD cohort of Phase 1 IMVT-1402 trial
- Immunovant price target raised to $48 from $30 at Truist
- Immunovant to Present at Upcoming Investor Conferences